Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Champions Oncology (CSBR) EBITDA (2016 - 2026)

Champions Oncology has reported EBITDA over the past 17 years, most recently at -$276000.0 for Q1 2026.

  • For Q1 2026, EBITDA fell 106.13% year-over-year to -$276000.0; the TTM value through Jan 2026 reached -$2.6 million, down 141.74%, while the annual FY2025 figure was $4.6 million, 161.9% up from the prior year.
  • EBITDA for Q1 2026 was -$276000.0 at Champions Oncology, down from $185000.0 in the prior quarter.
  • Over five years, EBITDA peaked at $4.5 million in Q1 2025 and troughed at -$2.6 million in Q1 2024.
  • A 5-year average of -$479823.5 and a median of -$284000.0 in 2022 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: tumbled 28028.57% in 2023 and later soared 274.58% in 2025.
  • Year by year, EBITDA stood at $7000.0 in 2022, then tumbled by 28028.57% to -$2.0 million in 2023, then soared by 137.44% to $732000.0 in 2024, then tumbled by 74.73% to $185000.0 in 2025, then crashed by 249.19% to -$276000.0 in 2026.
  • Business Quant data shows EBITDA for CSBR at -$276000.0 in Q1 2026, $185000.0 in Q4 2025, and -$527000.0 in Q3 2025.